Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011
United States
425 620 8501
https://www.athira.com
版塊: Healthcare
行業: Biotechnology
全職員工: 65
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Mark J. Litton M.B.A., Ph.D. | President, CEO & Director | 882.7k | 無 | 1968 |
| Mr. Andrew W. Gengos | CFO & Chief Business Officer | 396.16k | 無 | 1964 |
| Ms. Rachel P. Lenington M.B.A. | Chief Development Officer & COO | 578k | 無 | 1973 |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer | 123.67k | 無 | 1985 |
| Ms. Julie Rathbun | Head of Investor Relations | 無 | 無 | 無 |
| Mr. Mark F. Worthington J.D. | General Counsel & Corporate Secretary | 503.83k | 無 | 1966 |
| Ms. Samantha Willing | Chief People Officer | 無 | 無 | 無 |
| Dr. Javier San Martin M.D. | Chief Medical Officer | 無 | 無 | 1965 |
描述
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
公司管治
截至 2024年5月1日 止，Athira Pharma, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：5；股東權利：8；現金賠償：8。
